GenoMed, Inc. Scores 14th Victory Treating Neuroinvasive West Nile Virus In Humans

ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ -- GenoMed Inc. ("the Company" or "GenoMed") , a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it successfully treated its fourteenth patient with presumed West Nile virus encephalitis.

The patient is a previously healthy woman from Sacramento, California who developed fever, headache, and vomiting and was admitted to the hospital with presumed West Nile virus on Monday of this week. On Tuesday she began receiving GenoMed's protocol, and on Wednesday she was again alert and laughing. She was discharged from hospital yesterday.

The patient's Infectious Disease consultant knew about GenoMed's protocol. GenoMed's protocol was approved by the hospital's Institutional Review Board earlier this summer.

David Moskowitz MD, FACP, GenoMed's Chief Medical Officer and CEO, commented, "This patient demonstrated an extremely rapid resolution of her symptoms, several days faster than expected. Normally it takes 3-6 days to recover from West Nile virus meningo-encephalitis. This patient's recovery time was 24 hours."

During the past three summers, GenoMed has treated 17 patients, of whom this patient represents the 14th treatment success (82%).

To enroll in GenoMed's free clinical trial, which uses already existing, safe medication present in every drug store and hospital, just go to http://www.genomed.com and click on the link for the West Nile virus trial. GenoMed's approach may work against most viruses, including avian influenza.

About GenoMed

GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of end-stage emphysema; and begin to see success in treating cancer and autoimmune diseases. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II (see Section 2151 of Senate bill S. 975). GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians -- breast, colon, lung, ovarian, pancreatic, and prostate -- and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

CONTACT: David Moskowitz MD of GenoMed, Inc., +1-314-983-9938,dwmoskowitz@genomed.com

Web site: http://www.genomed.com/